{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "cabotegravir",
                    "events": "4",
                    "total person-years": "1956",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.20%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Overall",
                    "treatment": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "cabotegravir",
                    "events": "3",
                    "total person-years": "866",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.35%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age <25 years",
                    "treatment": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "cabotegravir",
                    "events": "1",
                    "total person-years": "1090",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.09%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Age \u226525 years",
                    "treatment": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method DMPA",
                    "treatment": "cabotegravir",
                    "events": "3",
                    "total person-years": "1009",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.30%, 0.16 (0.05\u20130.53), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method DMPA",
                    "treatment": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.10%, 0.16 (0.05\u20130.53), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method DMPA",
                    "treatment": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.10%, 0.16 (0.05\u20130.53), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method DMPA",
                    "treatment": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.10%, 0.16 (0.05\u20130.53), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method DMPA",
                    "treatment": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.10%, 0.16 (0.05\u20130.53), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method DMPA",
                    "treatment": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[2.10%, 0.16 (0.05\u20130.53), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method NET-EN",
                    "treatment": "cabotegravir",
                    "events": "1",
                    "total person-years": "175",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.57%, 0.22 (0.03\u20131.48), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method NET-EN",
                    "treatment": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[3.30%, 0.22 (0.03\u20131.48), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method NET-EN",
                    "treatment": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[3.30%, 0.22 (0.03\u20131.48), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method NET-EN",
                    "treatment": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[3.30%, 0.22 (0.03\u20131.48), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method NET-EN",
                    "treatment": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[3.30%, 0.22 (0.03\u20131.48), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Implant",
                    "treatment": "cabotegravir",
                    "events": "0",
                    "total person-years": "not specified",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0%, 0.06 (0.00\u20131.16), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Implant",
                    "treatment": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.32%, 0.06 (0.00\u20131.16), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Implant",
                    "treatment": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.32%, 0.06 (0.00\u20131.16), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Implant",
                    "treatment": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.32%, 0.06 (0.00\u20131.16), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Other",
                    "treatment": "cabotegravir",
                    "events": "0",
                    "total person-years": "not specified",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0%, 0.32 (0.01\u20139.89), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Other",
                    "treatment": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.66%, 0.32 (0.01\u20139.89), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Contraceptive method Other",
                    "treatment": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.66%, 0.32 (0.01\u20139.89), 0.87]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Body-mass index \u226430 kg/m2",
                    "treatment": "cabotegravir",
                    "events": "4",
                    "total person-years": "1389",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0.29%, 0.16 (0.06\u20130.45), 0.47]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Body-mass index \u226430 kg/m2",
                    "treatment": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "comparison": "cabotegravir"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[1.87%, 0.16 (0.06\u20130.45), 0.47]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Cabotegravir effectiveness",
                    "group": "Body-mass index >30 kg/m2",
                    "treatment": "cabotegravir",
                    "events": "0",
                    "total person-years": "not specified",
                    "comparison": "TDF-FTC"
                },
                "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
                "outcomes": "[0%, 0.05 (0.00\u20130.96), 0.47]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 18,
    "total_ground_truth_claims": 9,
    "number_of_matches": 9
}